Minerva Neurosciences | NERV - Operating Expenses


Minerva Neurosciences reported $4.52M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Adma Biologics USD 71.95M 7.75M Jun/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
AstraZeneca USD 11.55B 674M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Cipla INR 63.61B 1.3B Sep/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.44M 246K Jun/2026
CSL USD 5.7B 2.82B Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 18.93B 1.09B Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 89B 3.81B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 10.51B 598M Sep/2026
Takeda JPY 981.78B 36.71B Sep/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025